- $68.00m
- -$86.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.45 | ||
| Price to Tang. Book | 0.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -79.22% | ||
| Return on Equity | -59.64% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 7 | 4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Directors
- Steven Nichtberger CHM (59)
- Anup Marda CFO (43)
- Gwendolyn Binder-Scholl CEX (46)
- Michael Gerard GCN
- David Chang OTH (58)
- Arun Das OTH
- Scott Brun IND
- Mark Simon IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 3rd, 2017
- Public Since
- October 25th, 2019
- No. of Shareholders
- 68
- No. of Employees
- 161
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 50,743,101
- Address
- 2929 Arch Street, Suite 600, PHILADELPHIA, 19104
- Web
- https://www.cabalettabio.com/
- Phone
- +1 2677593100
- Contact
- Anup Marda
- Auditors
- Ernst & Young
Upcoming Events for CABA
Cabaletta Bio Inc Annual Shareholders Meeting
Cabaletta Bio Inc Annual Shareholders Meeting
Q2 2025 Cabaletta Bio Inc Earnings Release
Similar to CABA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Cabaletta Bio share price?
As of Today at 19:44 UTC, shares in Cabaletta Bio are trading at $1.34. This share price information is delayed by 15 minutes.
How has the Cabaletta Bio share price performed this year?
Shares in Cabaletta Bio last closed at $1.34 and the price had moved by -89.37% over the past 365 days. In terms of relative price strength the Cabaletta Bio share price has underperformed the S&P500 Index by -90.41% over the past year.
What are the analyst and broker recommendations for Cabaletta Bio?
The overall consensus recommendation for Cabaletta Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cabaletta Bio dividend yield?
Cabaletta Bio does not currently pay a dividend.
Does Cabaletta Bio pay a dividend?
Cabaletta Bio does not currently pay a dividend.
When does Cabaletta Bio next pay dividends?
Cabaletta Bio does not currently pay a dividend.
How do I buy Cabaletta Bio shares?
To buy shares in Cabaletta Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cabaletta Bio?
As of the previous close price of $1.34, shares in Cabaletta Bio had a market capitalisation of $68.00m.
Where are Cabaletta Bio shares listed?
Here are the trading details for Cabaletta Bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CABA
What kind of share is Cabaletta Bio?
Based on an overall assessment of its quality, value and momentum Cabaletta Bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cabaletta Bio share price forecast for 2025?
The analyst consensus target price for shares in Cabaletta Bio is $16.22. That is 1110.45% above the last closing price of $1.34.
Analysts covering Cabaletta Bio currently have a consensus Earnings Per Share (EPS) forecast of -$2.27 for the next financial year.
Find out moreWhat is the trend in the Cabaletta Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cabaletta Bio. Over the past six months, its share price has underperformed the S&P500 Index by -63.72%.
As of the last closing price of $1.34, shares in Cabaletta Bio were trading -59.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cabaletta Bio PE Ratio?
The Cabaletta Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cabaletta Bio?
Cabaletta Bio's management team is headed by:
- Steven Nichtberger - CHM
- Anup Marda - CFO
- Gwendolyn Binder-Scholl - CEX
- Michael Gerard - GCN
- David Chang - OTH
- Arun Das - OTH
- Scott Brun - IND
- Mark Simon - IND